Ubs Group Ag Verve Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 164,127 shares of VERV stock, worth $887,927. This represents 0.0% of its overall portfolio holdings.

Number of Shares

164,127

Previous 106,702 53.82%

Holding current value

$887,927

Previous $520,000 52.69%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$4.4 - $7.86 $252,670 - $451,360	57,425 Added 53.82%	164,127 $794,000
Q2 2024 Aug 13, 2024	SELL	$4.76 - $12.79 $881,942 - $2.37 Million	-185,282 Reduced 63.46%	106,702 $520,000
Q1 2024 May 13, 2024	BUY	$10.81 - $17.96 $958,122 - $1.59 Million	88,633 Added 43.59%	291,984 $3.88 Million
Q4 2023 Feb 09, 2024	BUY	$8.84 - $18.7 $1.06 Million - $2.25 Million	120,088 Added 144.23%	203,351 $2.83 Million
Q3 2023 Nov 09, 2023	SELL	$11.42 - $20.82 $54,941 - $100,165	-4,811 Reduced 5.46%	83,263 $1.1 Million
Q2 2023 Aug 11, 2023	SELL	$13.34 - $19.9 $36,831 - $54,943	-2,761 Reduced 3.04%	88,074 $1.65 Million
Q1 2023 May 12, 2023	SELL	$14.3 - $24.01 $2.19 Million - $3.67 Million	-152,939 Reduced 62.74%	90,835 $1.31 Million
Q4 2022 Feb 08, 2023	BUY	$17.85 - $40.7 $3.75 Million - $8.55 Million	210,071 Added 623.3%	243,774 $4.72 Million
Q3 2022 Nov 10, 2022	BUY	$15.63 - $41.49 $524,433 - $1.39 Million	33,553 Added 22368.67%	33,703 $1.16 Million
Q2 2022 Aug 10, 2022	SELL	$11.14 - $23.17 $1.18 Million - $2.46 Million	-106,101 Reduced 99.86%	150 $2,000
Q1 2022 May 16, 2022	BUY	$20.92 - $39.36 $1.71 Million - $3.22 Million	81,921 Added 336.71%	106,251 $2.42 Million
Q4 2021 Feb 14, 2022	BUY	$31.94 - $54.82 $671,698 - $1.15 Million	21,030 Added 637.27%	24,330 $897,000
Q3 2021 Nov 15, 2021	BUY	$46.0 - $73.99 $81,374 - $130,888	1,769 Added 115.55%	3,300 $155,000
Q2 2021 Aug 13, 2021	BUY	$31.92 - $60.25 $48,869 - $92,242	1,531 New	1,531 $92,000

Others Institutions Holding VERV

# of Institutions

186

Shares Held

73.3M

Call Options Held

85K

Put Options Held

215K

View Full List

About Verve Therapeutics, Inc.

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $324M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

More about VERV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account